LONDON May 23 (Reuters) - European regulators said on Friday they had recommended approval of Roche's drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic leukaemia, boosting the Swiss group's line-up of new cancer treatments.
The new medicine is an improved follow-on medicine to Roche's $7 billion-a-year Rituxan, or MabThera, and Roche is hoping to switch as many patients as possible to the newer product before Rituxan faces competition from cheaper copies.
Read more